🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Featured Article of the Month by Satapathy et al. in JNM demonstrating that low-dose capecitabine did not lead to superior radiographic responses when added to 177Lu-DOTATATE in patients with advanced grade 1/2 GEP-NETs.

omny.fm/shows/the-huge… .Such a cool experience to be a guest on the HUGE talking Detroit Lions, #SuperBowl, and BAMF Health with the legend himself. Forever grateful for this awesome opportunity.

Being presented at ASCO #GU25 ⬇️ Overall survival & QOL results from ENZA-p: [177Lu]Lu-PSMA-617 plus enzalutamide vs enzalutamide in metastatic castration-resistant #prostatecancer Louise Emmett Ian Davis Michael Hofman Martin Stockler ANZUP bit.ly/3ExZgPI

Reminder: ACRO wants to hear your opinions on Adaptive RT clinical practices / current reimbursement. You should have received the survey via SurveyMonkey. If you missed it, please respond here and we will get it to you: form.jotform.com/250415165529153 #ACROAdvocacy

Brandon Mancini kicking off a Radiopharma panel in Melrose 4 at #ACRO2025 ACRO - American College of Radiation Oncology ACROresident

SPECT deserves RESPECT: The potential of SPECT/CT to optimize patient outcomes with theranostics therapy. ow.ly/Tg2950Vgaij #NuclearMedicine #Theranostics #RPTherapy Louise Emmett

ACRO member Dr. Brandon Mancini spoke with CancerNetwork® about his experience and topics that resonated with him at The Radiation Oncology Summit: #ACRO2025. Check it out: cancernetwork.com/view/discussin…

The 2025 ACRO Annual Summit created opportunities for allowing outcome enhancements through the usefulness of treatment, according to Brandon Mancini, MD, MBA, FACRO. #radonc | Brandon Mancini cancernetwork.com/view/discussin…

"One of the major challenges, which is not specific to radiation oncology but [one that] gets brought up every year, is the potential for Medicare cost cutting for reimbursement," stated Brandon Mancini, MD, MBA, FACRO. Brandon Mancini | #ACRO2025 cancernetwork.com/view/2025-acro…

FDA expands the indication for a treatment for metastatic castration-resistant prostate cancer fda.gov/drugs/resource…

BIG NEWS! Yesterday the FDA expanded the indication for lutetium-177 vipivotide tetraxetan (Pluvicto), allowing its use before taxane-based chemotherapy. The new approval triples Pluvicto’s eligible patient population. More here: fda.gov/drugs/resource…

Adaptive radiation may help individualize therapy based on transient factors patients are faced with while receiving treatment for cancer. #RadOnc | Brandon Mancini cancernetwork.com/view/exploring…

Greater cancer treatment longevity enables oncologists the ability to form more impactful relationships with their patients. #RadOnc | Brandon Mancini hubs.li/Q03fDtFm0

NEW: Michigan true freshman QB Bryce Underwood surprised his high school security guard with a new car❤️ (via Bryce Jay Underwood) on3.com/college/michig…

Leading experts from Mass General Cancer Center, University of Michigan Health-West, MD Anderson Cancer Center, and AdventHealth—Dr. Jason Efstathiou, Dr. Brandon Mancini, Dr. Comron Hassanzadeh, and Bridget Koontz—discuss the diagnostic and clinical impact of PSMA PET in prostate cancer. Watch now:

In this expert-led discussion, panelists compare tracers like Axumin, Illuccix, Pylarify, and Posluma—highlighting differences in diagnostic accuracy, image quality, and clinical practicality. Leading experts from Mass General Cancer Center, University of Michigan Health-West, MD Anderson Cancer Center, and

How does imaging quality impact prostate cancer treatment decisions? In Episodes 4 & 5, experts from Mass General Cancer Center, University of Michigan Health-West, MD Anderson Cancer Center, and AdventHealth—Dr. Jason Efstathiou, Dr. Brandon Mancini, Dr. Comron Hassanzadeh, and Bridget Koontz examine the role of PSMA

Had the chance to speak with Brandon Mancini of BAMF Health about 212Pb-VMT-α-NET therapy in SSTR2-expressing NETs at #ASCO25. Key points included DLT observations at 1-year follow-up and early insights from the expansion cohort. Stay tuned for more! ASCO #NETs #oncology

"In the 9 patients that have 52 weeks or longer of follow-up, there seems to be really good activity with [212Pb]VMT-α-NET" - Brandon Mancini | #RadOnc hubs.li/Q03rmMFY0

Advances in imaging quality have reduced uncertainty, improving risk stratification and therapeutic precision Dr. Jason Efstathiou Brandon Mancini cancernetwork.com/view/imaging-q…